[1]Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130. [2]Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.[3]Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.[4]Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23(43):7274-7282.[5]Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.[6]Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988.[7]文加斌.NCI-H446人小细胞肺癌细胞株细胞亚群克隆异质性与肿瘤干细胞的实验研究[D].辽宁:大连医科大学,2009:1-58.[8]Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6):823-835.[9]Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67(10):4827-4833.[10]Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun. 2008;371(1):163-167.[11]Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504-514. [12]Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009; 36(3):446-453.[13]Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006; 351(4):820-824. [14]Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542-2556. [15]Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43(5):935-946.[16]Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3): 313-323.[17]中国知网.中国学术期刊总库[DB/OL].2013-3-10. https://www.cnki.net[18]程继荣,邹静,祖木热提•穆沙江.CDl33和CD45在非小细胞肺癌组织中的表达及临床意义[J].肿瘤基础与临床,2011,24(4): 284-286.[19]孙慧元,杨摇敏,郑茂金,等.非小细胞肺癌组织中CD133和ALDH1的表达及其临床意义[J].临床与实验病理学杂志,2012, 28(7):813-815.[20]倪静怡,杨磊,朱兴华,等.基因OCT4、CD133在非小细胞肺癌组织中的表达及临床意义[J].实用临床医药杂志,2012,16(19): 19-22.[21]张惠忠,魏益平,华平,等.非小细胞肺癌淋巴结转移和预后与CD133和CD147表达的关系[J].中华实验外科杂志,2007, 24(7): 873-874.[22]王树岗,曾志勇,杨胜生,等.CD133在83例人肺腺癌细胞中的表达研究[J].心肺血管病杂志,2012,31(6):727-729.[23]文加斌,张阳,王丽萍,等.NCI-H446人小细胞肺癌细胞株细胞亚群克隆与肿瘤干细胞的实验研究[J].实用癌症杂志,2009, 24(2): 114-116.[24]姚杰,王志刚,童文先,等.肿瘤干细胞标记物CD133和CD44在肺癌原发灶及转移淋巴结中的表达情况[J].西南国防医药,2010, 20(12):1300-1303.[25]Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol. 2004; 57(9):965-969. |